Alzheimer's drugs show 'trivial' benefit

टॉप scientists have delivered a significant blow to the pharmaceutical industry, suggesting that highly touted anti-amyloid treatments have 'trivial' effects on cognitive decline.

The analysis of 17 clinical trials found that while the drugs can clear amyloid plaques from the brain, this does not translate into noticeable improvements for those with mild impairment.

Critics of the review argue that it unfairly grouped failed older drugs with newer, recently approved treatments that show more promise.

The findings come at a critical time as health systems in the UK and US weigh the high cost of these medications against their actual clinical utility.